Skip to main content

Table 2 Baseline characteristics of patients who experienced or not clinical relapses during the study course

From: Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients

 Relapse yes (n = 31)Relapse no (n = 117)Significance
Gender (♀); patients (%)20 (64.51)72 (61.53)χ2 = 0.92, p = 0.761
Age (years); mean (SD)30.45 (± 7.66)38.02 (± 10.42)t = − 3.77, p < 0.001
EDSS*; mean (SD)1.32 (± 0.83)1.55 (± 0.86)t = − 1.34, p = 0.181
Enhancing lesions**; patients (%)18/31 (58)55/81 (67.9)χ2 = 1.36, p = 0.243
Naïve Treg percentage*; mean (SD)33 (± 14)28.16 (± 11.09)t = 2.03, p = 0.044
TregCM percentage*; mean (SD)42.63 (± 13.12)46.52 (± 8.17)t = − 2.04, p = 0.043
TregEM percentage*; mean (SD)23.39 (± 6.28)25.06 (± 8.10)t = 0.27, p = 0.290
Tr1 percentage*; mean (SD)3.83 (± 1.22)4.68 (± 2.13)t =− 2.10, p = 0.037
  1. SD standard deviation, Treg regulatory T cells, TregCM Treg central memory, TregEM Treg effector memory
  2. p-value calculation was done using Chi squared (χ2) or two independent sample t-test for categorical or continuous variables, respectively
  3. * Data determined at the pre-therapy time point
  4. ** These data are available for a subgroup of patients only